Aryl-oxadiazole Schiff bases: Synthesis, α-glucosidase in vitro inhibitory activity and their in silico studies

Aryl-oxadiazole Schiff bases: Synthesis, α-glucosidase in vitro inhibitory activity and their in silico studies

Show other versions (1)

α-Glucosidase enzyme is a therapeutic target for diabetes mellitus and its inhibitors play a vital role in the treatment of this disease. A new series of aryl-oxadiazole Schiff bases (1–18) were synthesized and evaluated for α-glucosidase inhibitory potential. Fifteen compounds 1–8, 11–13, and 15–18...

Full description

Bibliographic Details
Main Authors: Hussain, R. (Author), Imran, S. (Author), Kanwal (Author), Khan, K.M (Author), Miana, G.A (Author), Mosaddik, A. (Author), Nawaz, M. (Author), Rahim, F. (Author), Tabassum, N. (Author), Taha, M. (Author), Ullah, H. (Author), Wadood, A. (Author), Wahab, Z. (Author)
Format: Article
Language:English
Published: Elsevier B.V., 2020
Subjects:
Alpha glucosidase
Aryl-oxadiazole Schiff bases
Binding energy
Diabetes mellitus
Enzymes
Glucosidase
Inhibitory activity
Molecular docking
Molecular modeling
Schiff basis
Structure-activity relationship (SAR)
Structure-activity relationships
Synthesis
Synthesis (chemical)
Therapeutic targets
α-glucosidase
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items